PUBLIC CONTRACT · 2025
Ajuste direto para aquisição de I287, U41, U42 e U43
- Contract value
- €321,280.00
- Signed on
- 30 April 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11387935PUBLISHED SUBJECT
Ajuste direto para aquisição de I287- Infliximab doentes em tratamento [100 mg; pó p/a conc p/a sol p/a perf; frs], U41- Ustecinumab [45 mg/ 0,5 ml; sol inj; seringa] - doentes em tratamento, U42- Ustecinumab [90 mg; sol inj; seringa] - doentes em tratamento e U43- Ustecinumab [130 mg; sol inj; frs] - doentes em tratamento.
Parties involved
- Place of performance
- Portugal
- NUTS region
- PTZZZ - Extra-Regio NUTS 3 (Todos)
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- JANSSEN CILAG FARMACEUTICA, LDA. · Tax ID 500189412
Values and timeline
- Contract price
- €321,280.00
- Procedure base price
- €4,495,234.99
- Total effective price
- Not reported on Portal BASE
- Publication date
- 2 May 2025
- Award date
- 17 April 2025
- Signing date
- 30 April 2025
- Performance period
- 276 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- Yes
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7527358
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.